Cargando…

From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights

Although most same-stage non-alcoholic fatty liver disease (NAFLD) patients exhibit similar histologic sequelae, the underlying mechanisms appear to be highly heterogeneous. Therefore, it was recently proposed to redefine NAFLD to metabolic dysfunction-associated fatty liver disease (MAFLD) in which...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gatzios, Alexandra, Rombaut, Matthias, Buyl, Karolien, De Kock, Joery, Rodrigues, Robim M., Rogiers, Vera, Vanhaecke, Tamara, Boeckmans, Joost
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8773802/ https://www.ncbi.nlm.nih.gov/pubmed/35052840 http://dx.doi.org/10.3390/biomedicines10010161

Ejemplares similares

Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery
por: Boeckmans, Joost, et al.
Publicado: (2022)

Flow cytometric quantification of neutral lipids in a human skin stem cell-derived model of NASH
por: Boeckmans, Joost, et al.
Publicado: (2020)

Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
por: Boeckmans, Joost, et al.
Publicado: (2019)

Transcriptomics data of a human in vitro model of non-alcoholic steatohepatitis exposed to elafibranor
por: Boeckmans, Joost, et al.
Publicado: (2019)

Infections at the nexus of metabolic-associated fatty liver disease
por: Boeckmans, Joost, et al.
Publicado: (2021)

COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?
por: Boeckmans, Joost, et al.
Publicado: (2020)

Transcriptional Profile of Cytokines, Regulatory Mediators and TLR in Mesenchymal Stromal Cells after Inflammatory Signaling and Cell-Passaging
por: Merimi, Makram, et al.
Publicado: (2021)

Gene expression data from acetaminophen-induced toxicity in human hepatic in vitro systems and clinical liver samples
por: Rodrigues, Robim M., et al.
Publicado: (2016)

Inflammation Alters the Secretome and Immunomodulatory Properties of Human Skin-Derived Precursor Cells
por: De Kock, Joery, et al.
Publicado: (2020)

The Impact of Cell-Expansion and Inflammation on The Immune-Biology of Human Adipose Tissue-Derived Mesenchymal Stromal Cells
por: Buyl, Karolien, et al.
Publicado: (2020)

In Vitro Differentiation of Embryonic and Adult Stem Cells into Hepatocytes: State of the Art
por: Snykers, Sarah, et al.
Publicado: (2009)

Current Status of Human Adipose–Derived Stem Cells: Differentiation into Hepatocyte-Like Cells
por: Al Battah, Feras, et al.
Publicado: (2011)

Genetic and Epigenetic Modification of Rat Liver Progenitor Cells via HNF4α Transduction and 5’ Azacytidine Treatment: An Integrated miRNA and mRNA Expression Profile Analysis
por: Bolleyn, Jennifer, et al.
Publicado: (2020)

NAFLD/MAFLD: New Evidence
por: Mantovani, Alessandro, et al.
Publicado: (2023)

Editorial: The NAFLD-MAFLD conundrum
por: Dalbeni, Andrea, et al.
Publicado: (2023)

MAFLD: How is it different from NAFLD?
por: Gofton, Cameron, et al.
Publicado: (2023)

Comparison of MAFLD and NAFLD Characteristics in Children
por: Xing, Yunfei, et al.
Publicado: (2023)

COVID-19 and MAFLD/NAFLD: An updated review
por: Nowroozi, Ali, et al.
Publicado: (2023)

MAFLD and NAFLD in the prediction of incident chronic kidney disease
por: Kwon, So Yoon, et al.
Publicado: (2023)

The NAFLD–MAFLD debate through the lens of the Arab world
por: Tharwat, Mina, et al.
Publicado: (2022)

NAFLD vs MAFLD: South Asian NAFLD Patients don't Favor Name Change
por: Singh, Shivaram P, et al.
Publicado: (2022)

NAFLD and MAFLD as emerging causes of HCC: A populational study
por: Myers, Shuna, et al.
Publicado: (2021)

MAFLD Not NAFLD is Associated with Impairment of Health-related Quality of Life
por: Attia, Dina, et al.
Publicado: (2022)

Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition?
por: Lonardo, Amedeo
Publicado: (2021)

Cardiovascular and renal burdens among patients with MAFLD and NAFLD in China
por: Wang, Yuying, et al.
Publicado: (2022)

From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications
por: Boccatonda, Andrea, et al.
Publicado: (2023)

Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD
por: Chen, Jie, et al.
Publicado: (2023)

From NAFLD to MAFLD: a “redefining” moment for fatty liver disease
por: Zheng, Kenneth I., et al.
Publicado: (2020)

Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study
por: Baratta, Francesco, et al.
Publicado: (2021)

Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease
por: Musio, Alessandra, et al.
Publicado: (2023)

Increased risk of incident diabetes in patients with MAFLD not meeting the criteria for NAFLD
por: Park, So Hee, et al.
Publicado: (2023)

Association of Serum Vitamin C With NAFLD and MAFLD Among Adults in the United States
por: Xie, Zhi-Qin, et al.
Publicado: (2022)

Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm
por: Chua, Damien, et al.
Publicado: (2022)

Impact on Prevalence of the Application of NAFLD/MAFLD Criteria in Overweight and Normal Weight Patients
por: Ordoñez-Vázquez, Ana Luisa, et al.
Publicado: (2022)

Comparison of Clinical Characteristics and Outcomes of MAFLD and NAFLD in Chinese Health Examination Populations
por: Xu, Xin, et al.
Publicado: (2023)

NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care
por: Portincasa, Piero
Publicado: (2023)

Exposure of HepaRG Cells to Sodium Saccharin Underpins the Importance of Including Non-Hepatotoxic Compounds When Investigating Toxicological Modes of Action Using Metabolomics
por: Cuykx, Matthias, et al.
Publicado: (2019)

MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
por: Xian, Ying-Xin, et al.
Publicado: (2021)

MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis
por: Segura-Azuara, Nancy de los Ángeles, et al.
Publicado: (2022)

Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study
por: Niriella, Madunil Anuk, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1i84clkulfouk057vb2o5jo8f9